Harmonic Pharma and Institut Curie have set up a long term partnership.
Institut Curie possesses a genetically documented human tumors collection and has developed a unique expertise in Patient-Derived Xenograft (PDX) models that are predictive of clinical outcomes. Therefore, we have access to a suitable and powerful way of characterizing drug candidates while advancing them to a de-risked clinical development.
We are focusing our efforts on delivering innovations that serve patients burdened with difficult-to-treat cancers such as Non Small Cell Lung Cancer, (NSCLC) breast cancer and uveal melanoma.
Harmonic Pharma’s oncology program includes a novel target for lung cancer, assessment of efficacy in monotherapy and combinations with standard of care.